Precision Pharmacotherapy Group

Publications 9999

Bergstrom M, Muller M, Karlsson M, Scholz H, Vethe NT, Korsgren O (9999)
Comparing the Effects of the mTOR Inhibitors Azithromycin and Rapamycin on In Vitro Expanded Regulatory T Cells
Cell Transplant., UNSP 0963689719872488

Publications 2019

Brunet M, van Gelder T, Asberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millan O et al. (2019)
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Ther. Drug Monit., 41 (3), 261-307

Eide IA, Reinholt FP, Jenssen T, Hartmann A, Schmidt EB, Asberg A, Bergan S, Brabrand K, Syensson M (2019)
Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial
Am. J. Transplant., 19 (3), 790-800

Goll GL, Jorgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, Lundin KEA, Tveit KS, Lorentzen M, Berset IP, Fevang BTS, Kalstad S, Ryggen K, Warren DJ, Klaasen RA, Asak O, Baigh S, Blomgren IM, Brenna O, Bruun TJ, Dvergsnes K, Frigstad SO, Hansen IM, Hatten ISH, Huppertz-Hauss G et al. (2019)
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
J. Intern. Med., 285 (6), 653-669

Klaasen RA, Egeland EJ, Chan J, Midtvedt K, Svensson M, Boltad N, Fellstrom B, Holdaas H, Asberg A, Bergan S, Teethe NT, Warren DJ (2019)
A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients
Ther. Drug Monit., 41 (1), 11-18

Munkhaugen J, Ruddox V, Halvorsen S, Dammen T, Fagerland MW, Hernaes KH, Vethe NT, Prescott E, Jensen SE, Rodevand O, Jortveit J, Bendz B, Schirmer H, Kober L, Botker HE, Larsen AI, Vikenes K, Steigen T, Wiseth R, Pedersen T, Edvardsen T, Otterstad JE, Atar D (2019)
BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study
Am. Heart J., 208, 37-46

Munkhaugen J, Vethe NT, Fagerland MW, Dammen T, Perk J, Gjertsen E, Otterstad JE, Gullestad L, Bergan S, Husebye E (2019)
Statin-associated muscle symptoms in coronary patients: design of a randomized study
Scand. Cardiovasc. J., 53 (3), 162-168

Tuv SS, Vethe NT, Bergan S, Nordal K (2019)
Pharmacogenetics in personalised drug therapy
Tidsskr. Nor. Laegeforen., 139 (8), 700-702

Vethe NT, Munkhaugen J, Andersen AM, Husebye E, Bergan S (2019)
A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry
Ther. Drug Monit., 41 (1), 19-28

Publications 2018

Egeland EJ, Storset E, Robertsen I, Hermann M, Midtvedt K, Gustavsen MT, Klaasen R, Bergan S, Hartmann A, Asberg A (2018)
The Authors' Reply
Transplantation, 102 (1), e43-e44

Heldal K, Midtvedt K, Hartmann A, Reisaeter AV, Heldal TF, Bergan S, Salvador CL, Asberg A (2018)
Estimated glomerular filtration rate in stable older kidney transplant recipients-are present algorithms valid? A national cross-sectional cohort study
Transpl. Int., 31 (6), 629-638

Klaasen RA, Bergan S, Bremer S, Daleq L, Andersen AM, Midtvedt K, Skauby MH, Vethe NT (2018)
Longitudinal Study of Tacrolimus in Lymphocytes During the First Year After Kidney Transplantation
Ther. Drug Monit., 40 (5), 558-566

Krogstad V, Vethe NT, Robertsen I, Hasvold G, Ose AMD, Hermann M, Andersen AM, Chan J, Skauby M, Svensson MHS, Asberg A, Christensen H (2018)
Determination of Tacrolimus Concentration and Protein Expression of P-Glycoprotein in Single Human Renal Core Biopsies
Ther. Drug Monit., 40 (3), 292-300

Publications 2017

Bremer S, Vethe NT, Skauby M, Kasbo M, Johansson ED, Midtvedt K, Bergan S (2017)
NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation
Br. J. Clin. Pharmacol., 83 (11), 2494-2502

Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Storset E, Gustavsen MT, Reisaeter AV, Klaasen R, Bergan S, Holdaas H, Hartmann A, Asberg A (2017)
High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation
Transplantation, 101 (8), E273-E279

Midtvedt K, Bergan S, Reisaeter AV, Vikse BE, Asberg A (2017)
Exposure to Mycophenolate and Fatherhood
Transplantation, 101 (7), E214-E217

Midtvedt K, Holdaas H, Bergan S, Asberg A (2017)
Costimulation Blockade: America First, Canada Second ... What About Norway?
Am. J. Transplant., 17 (8), 2230

Olsen E, Bergan S, Mehl T, Burud I, Ekstrom KE, Di Sabatino M (2017)
Defect related radiative recombination in mono-like crystalline silicon wafers
Phys. Status Solidi A-Appl. Mat., 214 (8), 1700124

Salvador CL, Hartmann A, Asberg A, Bergan S, Rowe AD, Morkrid L (2017)
Estimating Glomerular Filtration Rate in Kidney Transplant Recipients: Comparing a Novel Equation With Commonly Used Equations in this Population
Transplant. Direct., 3 (12), e332

Skauby RH, Bjerre A, Saeves I, Vethe NT, Bremer S, Svarstad A, Bergan S (2017)
Prednisolone and Prednisone Pharmacokinetics in Pediatric Renal Transplant Recipients-A Prospective Study
Ther. Drug Monit., 39 (5), 472-482

Storset E, Hole K, Midtvedt K, Bergan S, Molden E, Asberg A (2017)
Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'
Br. J. Clin. Pharmacol., 83 (6), 1357-1358

Storset E, Hole K, Midtvedt K, Bergan S, Molden E, Asberg A (2017)
The CYP3A biomarker 4 beta-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation
Br. J. Clin. Pharmacol., 83 (7), 1457-1465

Storset E, Hole K, Midtvedt K, Bergan S, Molden E, Asberg A (2017)
Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance
Br. J. Clin. Pharmacol., 83 (6), 1350-1352

Publications 2016

Bergan S, Bremer S, Vethe NT (2016)
Drug target molecules to guide immunosuppression
Clin. Biochem., 49 (4-5), 411-418

Bjanes TK, Hjerto EM, Lonne L, Aronsen L, Berg JA, Bergan S, Berg-Hansen GO, Bernard JP, Burns ML, Fosen JT, Frost J, Hilberg T, Krabseth HM, Kvan E, Narum S, Westin AA (2016)
Pharmacology Portal: An Open Database for Clinical Pharmacologic Laboratory Services
Clin. Ther., 38 (1), 222-226

Brunet M, Shipkova M, van Gelder T, Wieland E, Sommerer C, Budde K, Haufroid V, Christians U, Lopez-Hoyos M, Barten MJ, Bergan S, Picard N, Lopez OM, Marquet P, Hesselink DA, Noceti O, Pawinski T, Wallemacq P, Oellerich M (2016)
Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation
Ther. Drug Monit., 38 1, S1-S20

Kloster-Jensen K, Sahraoui A, Vethe NT, Korsgren O, Bergan S, Foss A, Scholz H (2016)
Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids
J. Diabetes Res., 4196460

Picard N, Bergan S, Marquet P, van Gelder T, Wallemacq P, Hesselink DA, Haufroid V (2016)
Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs
Ther. Drug Monit., 38 1, S57-S69

Storset E, Asberg A, Hartmann A, Reisaeter AV, Holdaas H, Skauby M, Bergan S, Midtvedt K (2016)
Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience
Nephrology, 21 (10), 821-827

Storset E, von During ME, Godang K, Bergan S, Midtvedt K, Asberg A (2016)
Prediction of Fat-Free Mass in Kidney Transplant Recipients
Ther. Drug Monit., 38 (4), 439-446

Publications 2015

Bremer S, Fløisand Y, Brinch L, Gedde-Dahl T, Bergan S (2015)
Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning
Ther Drug Monit, 37 (4), 493-500
DOI 10.1097/FTD.0000000000000180, PubMed 25565670

Cehajic I, Bergan S, Bjordal K (2015)
Pharmacist assessment of drug-related problems on an oncology ward
Eur. J. Hosp. Pharm.-Sci. Pract., 22 (4), 194-197

de Graav GN, Bergan S, Baan CC, Weimar W, van Gelder T, Hesselink DA (2015)
Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation
Ther Drug Monit, 37 (5), 560-7
DOI 10.1097/FTD.0000000000000179, PubMed 25551406

Kloster-Jensen K, Vethe NT, Bremer S, Abadpour S, Korsgren O, Foss A, Bergan S, Scholz H (2015)
Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets invitro
Transpl. Int., 28 (10), 1152-1161

Robertsen I, Vethe NT, Midtvedt K, Falck P, Christensen H, Åsberg A (2015)
Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations
Ther Drug Monit, 37 (5), 675-80
DOI 10.1097/FTD.0000000000000185, PubMed 25565673

Robertsen I, Åsberg A, Ingerø AO, Vethe NT, Bremer S, Bergan S, Midtvedt K (2015)
Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed
Transplantation, 99 (3), 528-32
DOI 10.1097/TP.0000000000000384, PubMed 25148382

Salvador CL, Tondel C, Morkrid L, Bjerre A, Brun A, Bolann B, Brackman D, Bergan S (2015)
Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots
Scand. J. Clin. Lab. Invest., 75 (8), 710-716

Storset E, Asberg A, Skauby M, Neely M, Bergan S, Bremer S, Midtvedt K (2015)
Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients-A Prospective, Randomized Study
Transplantation, 99 (10), 2158-2166

 

 
Page visits: 725